Key facts
- It has raised $8.9M; the latest was PE Growth/Expansion ($8.9M) in Sep 2025.
- Notable investors include Finorpa, Grand Sud Ouest Capital, Caisse regionale du Credit Agricole Toulouse Midi-Toulousain, GSO Innovation, Horizon 2020 — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Genoskin
- ·The full record, as it builds
Funding rounds
No funding rounds for Genoskin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genoskin
Developer of ex vivo human skin models intended to facilitate the efficacy and toxicity testing of pharmaceutical, cosmetic, and chemical products. The company provides reliable human data before regulatory studies for human therapeutics, vaccines, medical devices, cosmetics, and chemicals and its technology permits stable and long-term ex vivo cultivation of fresh human skin biopsies without loss of tissue integrity, morphology, physiology, and cutaneous barrier function, enabling companies to test on real human tissue collected after surgery which is kept alive through an ex vivo culture system to avoid animal experiments.
- Sector
- Healthcare
- HQ
- Toulouse, France
- Employees
- 50
- Website
- genoskin.com/
- Ownership
- Privately Held (backing)
Genoskin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genoskin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genoskin in its N-PORT filings yet. We sweep new filings monthly.